EsTemp Implant
Spident Co., Ltd. · Decision date Sep 25, 2026
What did the FDA decide?
FDA recorded a substantial equivalence determination for K262983, EsTemp Implant, on September 25, 2026, with the submission received August 27, 2026. The applicant is Spident Co., Ltd. of Incheon, Republic of Korea. The device falls under 21 CFR 872.3275 (Dental Cement), Class II, product code EMA, in the Dental specialty. The letter states the device is substantially equivalent to legally marketed predicate devices for the indications for use stated in the enclosure; that enclosure is not reproduced in the available source text.
This is a 510(k) clearance, not a premarket approval. The letter permits marketing subject to general controls and notes registration, listing, labeling, medical device reporting and Quality Management System Regulation obligations, and that changes significantly affecting safety or effectiveness require a new premarket notification under 21 CFR 807.81. The source does not include the indications for use, predicate device identities, or any performance or clinical data, so the basis for the equivalence finding cannot be assessed here.
The available material does not describe the device's composition, design, or intended clinical use beyond its regulation and product code, and no clinical or efficacy conclusions are drawn.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262983
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Spident Co., Ltd.
- Product code
- EMA
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cement, Dental.
- Applicant
- Spident Co., Ltd.
- Product code
- EMA
- FDA device class
- 2
FDA decision timeline
K262983 received
Application receipt date recorded by FDA.
K262983 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Spident Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Incheon
Sources and methodology
- Original FDA record: K262983
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records